Effect of Denileukin Diftitox on Immune System in CTCL Patients

Completed

Conditions studied: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides

In brief

This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. Blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.

Key facts

Study ID

NCT00254332

Run by

University of Pittsburgh

People needed

10

Starts

2005-11-01

Expected to finish

2007-09-01

Last updated by the study team

2015-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 and older
• diagnosed with CTCL
• able and willing to provide informed consent
• will be receiving denileukin diftitox per standard guidelines

You may not qualify if…

• prior history of receiving Ontak
• pregnancy

Where it is running

• University of Pittsubrgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.